

July 27, 2022

To
The Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400001
Company Code No. 526301

Dear Sir/Madam

Subject: Outcome of the Board Meeting held on July 27, 2022.


We hereby inform you that, the Board of Directors in their meeting held today i.e. on Wednesday July 27, 2022 has inter-alia considered and approved:

1. The Un-audited Standalone and Consolidated Financial Results of the Company for the first quarter ended June 30, 2022.
The aforesaid financial results together with the Limited review reports issued by M/s. M. Anandam & Co., Chartered Accountants, Statutory Auditors of the Company are enclosed.

The Meeting commenced at 02.30 p.m. and concluded at 03.20 p.m.

Kindly take the same on record.

Thanking You
For Medinova Diagnostic Services Limited


Anusha Kanumuru
Company Secretary
Encl.: As above



M.ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results
of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

Review Report to the Board of Directors
Medinova Diagnostic Services Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited (the "Company") for the quarter ended 30th June, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

7 'A', SURYA TOWERS, SARDAR PATEL ROAD, SECUNDERABAD – 500003.
PHONE: 2781 2377, 2781 2034, FAX:2781 2091

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Madhuri
Chimalgi

Digitally signed by
Madhuri Chimalgi
Date: 2022.07.27 14:57:12
+05'30'

Madhuri Chimalgi

Partner

Membership Number: 235955

UDIN: 22235955ANSFVL9947

Place: Secunderabad

Date: 27-07-2022

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No.7-1-58/A/ FF/8 , Flat/Unit No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	Income:				
	(a) Revenue from Operations	193.41	224.99	428.00	1,151.38
	(b) Other Income	3.54	5.12	2.75	21.74
	Total Income	196.95	230.11	430.75	1,173.12
2	Expenses				
	(a) Cost of Materials Consumed	33.88	37.74	53.86	243.52
	(b) Employee Benefits Expense	46.27	44.70	45.00	181.99
	(c) Testing Fees	10.06	24.86	119.47	174.80
	(d) Finance Costs	14.34	12.07	9.59	41.03
	(e) Depreciation and amortisation expenses	5.41	6.83	6.23	26.01
	(f) Other Expenses	72.15	67.99	61.74	250.38
	Total Expenses	182.11	194.19	295.89	917.73
3	Profit before Tax [1-2]	14.84	35.92	134.86	255.39
4	Tax Expense				
	(a) Current Tax	3.12	5.84	33.76	60.46
	(b) Earlier Year's Tax	-	10.09	-	11.23
	(c) Deferred Tax	0.63	(5.91)	(5.83)	(23.70)
	Total tax expense	3.75	10.02	27.93	47.99
5	Profit for the period (3-4)	11.09	25.90	106.93	207.40
6	Other Comprehensive Income				
	Items that will not be reclassified to Profit or Loss (Net of tax)				
	Remeasurement of defined benefit plans	-	2.75	(0.22)	2.09
	Income tax relating to above	-	(0.53)	-	(0.53)
7	Total Comprehensive Income for the period (5+6)	11.09	28.12	106.71	208.96
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)				
	a) Basic (Rs.)	0.11	0.26	1.07	2.08
	b) Diluted (Rs.)	0.11	0.26	1.07	2.08

Notes

1. The above standalone financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 27th July, 2022. The Statutory Auditors of the Company have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015.

3. The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".

4. Previous period figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable

For MEDINOVA DIAGNOSTIC SERVICES LTD

SUNIL CHANDRA
KONDAPALLY

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place: Hyderabad
Date: 27.07.2022

M.ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Consolidated Unaudited Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

Review Report to the Board of Directors
Medinova Diagnostic Services Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Medinova Diagnostic Services Limited ("the Holding Company") and its wholly owned subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2022 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the wholly owned subsidiary, Medinova Millenium MRI Services LLP.

7 'A', SURYA TOWERS, SARDAR PATEL ROAD, SECUNDERABAD – 500003.
PHONE: 2781 2377, 2781 2034, FAX:2781 2091

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

**Madhuri
Chimalgi**

Digitally signed by
Madhuri Chimalgi
Date: 2022.07.27
15:00:19 +05'30'

Madhuri Chimalgi
Partner
Membership Number: 235955

UDIN: 22235955ANSGEQ3813

Place: Secunderabad
Date: 27-07-2022

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No.7-1-58/A/ FF/8 , Flat/Unit No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	Income:				
	(a) Revenue from Operations	246.02	269.86	454.11	1320.19
	(b) Other Income	1.79	3.42	0.95	14.64
	Total Income	247.81	273.28	455.06	1334.83
2	Expenses				
	(a) Cost of Materials Consumed	36.89	40.65	56.44	254.70
	(b) Employee Benefits Expense	50.82	48.78	49.00	198.27
	(c) Testing Fees	9.73	24.32	119.47	173.89
	(d) Finance Costs	16.38	14.18	12.55	50.94
	(e) Depreciation	10.71	13.59	13.47	54.65
	(f) Other Expenses	91.01	86.14	78.13	322.69
	Total Expenses	215.54	227.66	329.06	1055.14
3	Profit before Tax	32.27	45.62	126.00	279.69
4	Tax Expense				
	(a) Current Tax	3.12	5.84	33.76	60.46
	(b) Earlier Year's Tax	0.00	10.09	-	11.23
	(c) Deferred Tax	(0.64)	(7.30)	(7.36)	(30.06)
	Total tax expense	2.48	8.63	26.40	41.63
5	Profit for the period (3-4)	29.79	36.99	99.60	238.06
6	Other Comprehensive Income				
	Items that will not be reclassified to Profit or Loss (Net of tax)				
	Remeasurement of defined benefit plans	-	2.75	(0.22)	2.09
	Income tax relating to above	-	(0.53)	-	(0.53)
7	Total Comprehensive Income for the period (5+6)	29.79	39.21	99.38	239.62
	Net Profit attributable to:				
	(a) Owners of the Company	29.79	34.56	102.90	226.82
	(b) Non Controlling Interest	-	2.43	(3.30)	11.24
	Other Comprehensive Income attributable to:				
	(a) Owners of the Company	-	2.22	(0.22)	1.56
	(b) Non Controlling Interest	-	-	-	-
	Total Comprehensive Income attributable to:				
	(a) Owners of the Company	29.79	36.78	102.68	228.38
	(b) Non Controlling Interest	-	2.43	(3.30)	11.24
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)				
	a) Basic (Rs.)	0.30	0.35	1.03	2.27
	b) Diluted (Rs.)	0.30	0.35	1.03	2.27

Notes

- The above Consolidated financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 27th July, 2022. The Statutory Auditors of the Company have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above results include the results of the wholly owned subsidiary, Medinova Millennium MRI Services LLP
- The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- The Group has prepared consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".
- Previous period figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable.

For MEDINOVA DIAGNOSTIC SERVICES LTD

SUNIL CHANDRA
KONDAPALLY

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place: Hyderabad
Date : 27.07.2022